# Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

> **NCT03312751** · PHASE3 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 35 (actual)

## Conditions studied

- Primary Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** Emapalumab

## Key facts

- **NCT ID:** NCT03312751
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-06
- **Primary completion:** 2021-08-18
- **Final completion:** 2022-09-14
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312751, "Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03312751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*